Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters


Database
Language
Year of publication
Document type
Publication year range
1.
Article in English | MEDLINE | ID: mdl-24177607

ABSTRACT

Acitretin, a synthetic retinoid has gradually replaced etretinate in today's dermatologic practice because of its more favorable pharmacokinetics. Acitretin over the past 20 years has proven useful in a number of difficult-to-treat hyperkeratotic and inflammatory dermatoses and nonmelanoma skin cancers. It is effective both as monotherapy and in combination with other drugs for hyperkeratotic disorders. It is considered to be an established second line treatment for psoriasis and exerts its effect mainly due to its antikeratinizing, antiinflammatory, and antiproliferative effect. Its antineoplastic properties make it a useful agent for cancer prophylaxis. Evidence-based efficacy, side-effect profile, and approach to the use of acitretin would be discussed in this review. In addition to its approved uses, the various off label uses will also be highlighted in this section. Since its use is limited by its teratogenic potential and other adverse effects, including mucocutaneous effects and hepatotoxicity, this review would summarize the contraindications and precautions to be exercised before prescribing acitretin.


Subject(s)
Acitretin/administration & dosage , Dermatology/methods , Keratolytic Agents/administration & dosage , Skin Diseases/drug therapy , Acitretin/pharmacokinetics , Animals , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/pharmacokinetics , Cell Differentiation/drug effects , Cell Differentiation/physiology , Dermatology/trends , Humans , Keratolytic Agents/pharmacokinetics , Precancerous Conditions/pathology , Precancerous Conditions/prevention & control , Skin Absorption/drug effects , Skin Absorption/physiology , Skin Diseases/pathology
SELECTION OF CITATIONS
SEARCH DETAIL